Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Analysis of survival outcomes in patients with pancreatic cancer who underwent upfront surgery.
Authors
Jae Hyup Jung
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea;
Jae Hyup Jung , Jinkyeong Park , Jinwoo Ahn , Bomi Kim , Kwangrok Jung , Jong-Chan Lee , Jin-Hyeok Hwang , Jaihwan Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 679)
DOI
10.1200/JCO.2023.41.4_suppl.679
Abstract #
679
Poster Bd #
J4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Clinical relevance of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma who underwent surgery following neoadjuvant modified FOLFIRINOX.
First Author: So Heun Lee
Poster
2020 ASCO Virtual Scientific Program
Survival outcomes of patients with resectable pancreatic cancer treated with upfront surgery versus neoadjuvant chemotherapy: A retrospective tertiary care center experience.
First Author: Fang Liu
Poster
2020 Gastrointestinal Cancers Symposium
Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System.
First Author: Timil Patel
Poster
2018 ASCO Annual Meeting
Adjuvant treatment for resected sub-centimeter T1 pancreatic cancer.
First Author: Walid Labib Shaib